DOI: https://doi.org/10.15674/0030-59872010273-74

An experience of using Rivaroxaban (Xarelto®) in the treatment of lower extremity fractures

Vladislav Palamarchuk, Konstantin Bulavin

Abstract


The article contains an analysis of the results of prevention of venous thrombembolism (up to 35 days) in patients with fractures of their femoral and tibial bones, who were subjected to osteosynthesis. Two groups of patients were compared: the 1st was recommended to take Clexane, the 2nd one took Rivaroxaban (Xarelto(R)). In outpatient conditions, the prevention of venous thrombembolism lasted in 12.5 % of patients from the 1st group, and in 70.8 % from the 2nd one.


Keywords


Rivaroxaban; femur fractures; shin fractures; venous thrombembolism

References


Баешко А.А. Послеоперационный тромбоз глубоких вен нижних конечностей и тромбоэмболия легочной артерии. Эпидемиология. Этиопатогенез. Профилактика [Текст] / А.А. Баешко. — М.: Триада-Х, 2000. — 136 с.

Бокарев И.Н. Венозный тромбоэмболизм: лечение и профилактика [Электронный ресурс] / И.Н. Бокарев, Л.В. Попова, Т.Б. Кондратьев. — Режим доступа: http: // www.consilium-medicum.com /media /surgery /05_01/ 5. shtml.

Вырва О. Е. Сравнительная оценка эффективности ривароксабана и эноксапарина в профилактике тромбообразования после эндопротезирования тазобедренного сустава. Результаты исследований RECORD1 [Текст] / О.Е. Вырва // Ортопед. травматол. — 2009. — № 3. — С. 97–100.

Малиновский Н.Н. Возможна ли надежная профилакти¬ка послеоперационных венозных тромбоэмболических осложнений? [Текст] / Н.Н. Малиновский // Хирургия. — 2001. — № 1. — С. 6–11.

The prevalence ofrisk factors for venous thromboembolism amonghospitalpatients [Text] / F.A. Anderson, H.B. Wheeler, R.J. Goldbergetal. // Arch. Intern. Med. — 1992. — Vol. 152. — P. 1660–1664.

Fondaparinux compared with enoxaparinfor the preventionofvenous thromboembolism after hip fracture surgery [Text] / B.I. Eriksson, K.A. Bauer, M.R. Lassenetal. // N. Engl. J. Med. — 2001. — Vol. 345. — P. 1298–1304.

Eriksson B.I. Oralanticoagulants indevelopment: focus onthromboprophylaxis inpatientundergoingorthopedic surgery [Text] / B.I. Eriksson, D.J. Quinlan// Drugs. — 2006. — Vol. 66. — P. 1411–1429.

Rivaroxabanfor thromboprophylaxis after orthopedic surgery: pooled analysis oftwostudies [Text] / W.D. Fisher, B.I. Eriksson, K.A. Bauer etal. // Thromb. Haemost. — 2007. — Vol. 97. — P. 931–937.

Pulmonary embolism: epidemiology [Text] / C. Giuntini, G. Di Ricco, Marini et al. // Chest. — 1995. — Vol. 107. — P. 3–9.

Turpie A.G. Venous thromboembolism: pathophysiology, clinicalfeatures, and prevention[Text] / A.G. Turpie, B.S. Chin, G.Y. Lip. — Br Med. J. — 2002. — Vol. 325. — P. 887–890.




Copyright (c) 2014 Vladislav Palamarchuk, Konstantin Bulavin

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.